CN111803613A - 一种治疗脱发及头发再生的中药组合物 - Google Patents
一种治疗脱发及头发再生的中药组合物 Download PDFInfo
- Publication number
- CN111803613A CN111803613A CN202010807949.8A CN202010807949A CN111803613A CN 111803613 A CN111803613 A CN 111803613A CN 202010807949 A CN202010807949 A CN 202010807949A CN 111803613 A CN111803613 A CN 111803613A
- Authority
- CN
- China
- Prior art keywords
- parts
- active ingredient
- weight
- hair
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 48
- 231100000360 alopecia Toxicity 0.000 title claims abstract description 41
- 230000003660 hair regeneration Effects 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title abstract description 29
- 230000001737 promoting effect Effects 0.000 title abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 58
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 21
- 235000008397 ginger Nutrition 0.000 claims abstract description 21
- 241000234314 Zingiber Species 0.000 claims abstract description 19
- 210000004369 blood Anatomy 0.000 claims abstract description 19
- 239000008280 blood Substances 0.000 claims abstract description 19
- 241000287828 Gallus gallus Species 0.000 claims abstract description 14
- 241001522129 Pinellia Species 0.000 claims abstract description 13
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 11
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 40
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 claims description 21
- 239000010282 Emodin Substances 0.000 claims description 21
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 claims description 21
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 claims description 21
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 claims description 21
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical group C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims description 21
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 claims description 21
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 claims description 21
- 229940076810 beta sitosterol Drugs 0.000 claims description 20
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 20
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 20
- 229940109262 curcumin Drugs 0.000 claims description 20
- 235000012754 curcumin Nutrition 0.000 claims description 20
- 239000004148 curcumin Substances 0.000 claims description 20
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 20
- 229950005143 sitosterol Drugs 0.000 claims description 20
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 20
- YWJXCIXBAKGUKZ-HJJNZUOJSA-N Bergenin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]2C3=C(O)C(OC)=C(O)C=C3C(=O)O[C@@H]21 YWJXCIXBAKGUKZ-HJJNZUOJSA-N 0.000 claims description 19
- XULPLJSODQQHPH-UHFFFAOYSA-N Bergenin Natural products OCC1OC2C(OC(=O)c3cc(O)c(CO)c(O)c23)C(O)C1O XULPLJSODQQHPH-UHFFFAOYSA-N 0.000 claims description 19
- 102000001554 Hemoglobins Human genes 0.000 claims description 18
- 108010054147 Hemoglobins Proteins 0.000 claims description 18
- 235000013922 glutamic acid Nutrition 0.000 claims description 18
- 239000004220 glutamic acid Substances 0.000 claims description 18
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 229940098465 tincture Drugs 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 claims description 10
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 claims description 10
- 229930001895 zingiberene Natural products 0.000 claims description 10
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 claims description 8
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 claims description 8
- 241001289529 Fallopia multiflora Species 0.000 claims description 6
- 230000003676 hair loss Effects 0.000 claims description 6
- 241000906579 Actaea cimicifuga Species 0.000 claims description 5
- 208000024963 hair loss Diseases 0.000 claims description 5
- 241000243684 Lumbricus Species 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 229940104299 cimicifugae rhizoma Drugs 0.000 claims description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 230000003659 hair regrowth Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 30
- 239000003814 drug Substances 0.000 abstract description 18
- 210000004209 hair Anatomy 0.000 abstract description 17
- 240000001341 Reynoutria japonica Species 0.000 abstract description 14
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract description 14
- 230000003779 hair growth Effects 0.000 abstract description 9
- 230000003213 activating effect Effects 0.000 abstract description 7
- 241000206501 Actaea <angiosperm> Species 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 3
- 210000002435 tendon Anatomy 0.000 abstract description 3
- 210000003205 muscle Anatomy 0.000 abstract description 2
- 230000002040 relaxant effect Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241000721047 Danaus plexippus Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 23
- 210000003780 hair follicle Anatomy 0.000 description 14
- 239000003921 oil Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 210000004761 scalp Anatomy 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 239000000284 extract Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 239000001841 zingiber officinale Substances 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 241000123982 Astilbe chinensis Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 244000286838 Eclipta prostrata Species 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000830535 Ligustrum lucidum Species 0.000 description 2
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- 241000905368 Actaea rubra Species 0.000 description 1
- 206010001766 Alopecia totalis Diseases 0.000 description 1
- 241001614060 Amynthas aspergillus Species 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241001208462 Ophisternon bengalense Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- 241001522232 Pinellia ternata Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 241000220151 Saxifragaceae Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- BBJIPMIXTXKYLZ-UHFFFAOYSA-N beta-aminoglutaric acid Natural products OC(=O)CC(N)CC(O)=O BBJIPMIXTXKYLZ-UHFFFAOYSA-N 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940102465 ginger root Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000001150 spermicidal effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗脱发及头发再生的中药组合物,该组合物由含有首乌、生姜、红升麻、生半夏、地龙、乌骨鸡血的活性成分和火酒50%制成。本发明通过合理的君臣佐使原则来筛选组合物的用药处方,主要是发挥首乌、生姜活性成分活性舒筋活血、补益精血、滋润发毛、促进毛发生长功效,再结合其他组分活性成分活性发表透疹、清热解毒、升举阳气、活血通络的作用,功效相调,加上特定比例的用药用量,使整个组合物处方群药的力合达到协同增效的效果,与现有技术比较,本发明以其独特的功效促进毛囊再生,恢复毛囊再生功能,无毒副作用。
Description
技术领域
本发明涉及中药组合物领域,特别是涉及一种治疗脱发及头发再生的中药组合物及其制备方法。
背景技术
随着现代社会竞争压力的不断增大,人们的工作节奏越来越快。近年来,白发、脱发人群年轻化趋势日益明显。脱发也成为现代人们越来越重视和关注的问题。正常脱落的头发都是处于退行期及休止期的毛发,由于进入退行期与新进入生长期的毛发不断处于动态平衡,而病理性脱发是指头发异常或过度的脱落,造成脂溢性脱发、早秃、秃顶及斑秃、全秃等脱发的症状。
目前,市场上治疗脱发生发的药物多而乱,由于对脱发的原因研究不透,造成现有的止脱生发药物不能标本兼治,不仅价格高,而且停药后容易复发,效果不理想。
经查文献,在中国发明专利说明书CN 201210237564.8中公开了一种防脱生发中药组合物及其制备方法。包括下述重量份的组分:人参50-180份,侧柏叶50-180份,何首乌20-120份,甘草10-70份,老姜10-50份,骨碎补50-180份,旱莲草30-120份,冬虫夏草5-50份,女贞子20-80份。现有文献报道,多种中药材中分别以某一成分或某些成分起主导作用,这些成分共同协调增效,使该组合物对治疗脱发有一定效果。首先对于多种中药材提取制备所得组合物并不清楚其中起药效作用的有效成分,而且,采用该专利技术粉碎、醇提、浓缩等对中药材进行提取所得的有效成分并不一定能达到所述疗效。
不论使用何种药材提取方法,得到的是药材的总提取物,不光含有效的成分,如挥发油类、黄酮类,还有其他无效成分,这必将导致药物的使用剂量大,并且各种成分的作用机理也不明确,这正是该类药物在市场上应用的局限性所在。而且,各种有效成分的用量配比也不清楚。因此,对中药材的有效成分单体的研究作进一步的深入,是对治疗脱发及头发再生产品的又一次开发,具有重要意义。
发明内容
本发明所要解决的技术问题是克服现有生发酊制剂中药材用量大、有效成分及其作用机理不明确的缺陷,提供一种疗效迅速、安全、质量可控的治疗脱发及头发再生的中药组合物及其制备方法。
针对现有技术的不足,本发明采用首乌、生姜、红升麻、生半夏、地龙、乌骨鸡血6味中药材所得提取物的活性成分以及火酒的处方组成,明确了各治疗成分,具有良好的活化毛囊组织、促进头皮新陈代谢、补益精血、清热解毒、乌须发、促进毛发生长的功效,在治疗脱发及头发再生方面取得了意想不到的治疗效果。
具体地,本发明是由以下技术方案实现的:
一种治疗脱发及头发再生的药物组合物,含有首乌活性成分0.04-0.08份、生姜活性成分0.03-0.10份、红升麻活性成分0.11-0.17份、生半夏活性成分0.01-0.04份、地龙活性成分0.007-0.11份、乌骨鸡血活性成分0.008-0.012份、火酒5-10份。
进一步地,按重量份计算,含有首乌活性成分0.06份、生姜活性成分0.07份、红升麻活性成分1.5份、生半夏活性成分0.03份、地龙活性成分0.009份、乌骨鸡血活性成分0.01份、火酒5-10份;
前述的首乌活性成分为大黄素;前述的生姜活性成分为姜黄素、姜烯油;前述的红升麻活性成分为岩白菜素;前述的生半夏活性成分为β-谷甾醇;前述的地龙活性成分为谷氨酸;前述的乌骨鸡血活性成分为血红蛋白。
进一步地,按重量份计算,含大黄素0.04-0.08份、姜黄素0.01-0.04份、姜烯油0.02-0.06份、岩白菜素0.11-0.17份、β-谷甾醇0.01-0.04份、谷氨酸0.007-0.11份、血红蛋白0.008-0.012份、火酒5-10份。
优选地,含大黄素0.05-0.07份、姜黄素0.02-0.04份、姜烯油0.03-0.06份、岩白菜素0.12-0.16份、β-谷甾醇0.02-0.04、谷氨酸0.008-0.10份、血红蛋白0.009-0.011份、火酒5-10份。
优选地,按重量份计算,含大黄素0.06份、姜黄素0.03份、姜烯油0.04份、岩白菜素0.15份、β-谷甾醇0.03、谷氨酸0.009份、血红蛋白0.01份、火酒5-10份。
再进一步地,由上述技术方案所述的药物组合物和辅料制成,其剂型为酊剂。
再进一步地,通过上述步骤制得的药物组合物,加入3-5倍的40-55%乙溶液,搅拌溶解,即得。
再进一步地,该药物制剂在治疗脱发及头发再生中的应用。
本发明提供了上述方法制备而得的酊剂。
本发明所用原料药及活性成分,药理性能如下:
首乌:又名野苗、交藤、交茎、夜合、地精、桃柳藤、赤葛、九真藤、芮草、蛇草、陈知白、马肝石、九真藤、疮帚等,有雌雄二种(赤,白二种),为蓼科植物,可补益精血、乌须发、强筋骨、补肝肾,状如人形,可促进毛发生长的功效,故称何首乌,其块根入药,可安神、养血、活络,解毒,解毒、消痈,经查药典记载,首乌的使用量约10-15g,其中活性成分大黄素对于脱发及头发再生有治疗功效,查《贵州省中药材民族药材质量标准2003版》记载,其中大黄素的百分含量不低于0.050%。
生姜:为姜科植物姜的新鲜根茎,别名:姜根、百辣云、勾装指、因地辛、炎凉小子、鲜生姜、蜜炙姜、生姜汁、姜,具有舒筋活血、散寒解表,经查药典记载,生姜的使用量约2-6g,其中活性成分姜黄素、姜烯油可以使头部皮肤血液循环正常化,促进头皮新陈代谢,活化毛囊组织,有效地防止脱发、白发,刺激新发生长,并可抑制头皮痒,强化发根,经查文献,其中活性成分姜黄素含量约为3%-6%、姜烯油含量约为0.25%-1.2%。
红升麻:为虎耳草科植物落新妇和大落新妇的根茎,别名:黄力花、接骨草、泽兰、小升麻、金毛三七、消食丹、三角钻、水升麻、水三七、金毛狗、乌足升麻,落新妇根和根茎含岩白菜素(bergenin),大落新妇根和根茎亦含岩白菜素,经查《中华本草》、《中药大辞典》红升麻使用量约9-15g,其中活性成分岩白菜素,具有活血止痛,祛风除湿,强筋健骨,解毒作用,研究实验显示,其中岩白菜素含量大约为1.0%-1.5%。
生半夏:半夏为天南星科多年生草本植物半夏的块茎,功效为燥湿化痰、降逆止呕、消痞散结,用于痰多咳喘、痰饮眩悸、风痰眩晕、痰厥头痛、呕吐反胃、胸脘痞闷、梅核气等,生用可外治痈肿痰核,姜半夏多用于降逆止呕,经查相关文献显示,生半夏的使用量约为15-50g,其中有效成分β-谷甾醇可治皮肤瘙痒及皮肤溃疡,对头皮有良好的保护和治疗作用,其含量约为0.16%。
地龙:别名:蚯蚓干、曲鳝,为钜蚓科动物参环毛蚓Pherelima aspergillum(Perrier)的干燥体,能舒张支气管,并对抗组胺和毛果芸香碱引起的支气管收缩;对肾性高血压有显著的降压作用。此外还有收缩子宫、镇静、抗惊厥、解热、抗血栓形成、抗凝血、抗心律失常、抗肿瘤、杀精、镇痛等作用,主治清热定惊,通络,平喘,利尿,用于高热神昏,惊痫抽搐,关节痹痛,肢体麻木,半身不遂,肺热喘咳,尿少水肿;高血压,经查药典记载,地龙的使用量约4.5-9g,其中有效成分谷氨酸,作为营养药物可用于皮肤和毛发,用于生发剂,能被头皮吸收,预防脱发并使头发新生,对毛乳头、毛母细胞有营养功能,并能扩张血管,增强血液循环,有生发防脱发功效。用于皮肤,对治疗皱纹有疗效,其含量约为6%。
乌骨鸡血:别名乌鸡、药鸡、武山鸡、羊毛鸡、绒毛鸡、松毛鸡、黑脚鸡、丛冠鸡、穿裤鸡、竹丝鸡,为雉科动物,具补肝肾、益气血、退虚热功效,主治虚劳赢瘦、骨蒸痨热、消渴、遗精、久泻、久痢、崩中、带下,其鸡血含血红蛋白(hemoglobin)10.3g/100ml,鸡的红细胞每克干物含维生(vitamin)K8D.G.u,血浆每克干物含20D.G.u。
本发明至少具有下列优点及有益效果:
本发明是一种治疗脱发及头发再生的中药组合物,直接采用首乌、生姜、红升麻、生半夏、地龙、乌骨鸡血6味中药材所提取物活性成分以及火酒,明确了处方中活性成分及处方的用量配比,具有良好的活化毛囊组织、促进头皮新陈代谢、补益精血、清热解毒、乌须发、促进毛发生长的功效,在治疗脱发及头发再生方面取得了意想不到的治疗效果,同时,解决了采用传统提取工艺制得的药物使用药材用量大、不完全等问题,并改善了单独使用任一种药物可能导致的副作用,使药物疗效更安全、更快、更强。
具体实施方式
本发明的药物组合物或药物制剂,直接采用首乌、生姜、红升麻、生半夏、地龙、乌骨鸡血6味中药药材的活性成分,尤其是优选首乌活性成分中大黄素的用量;生姜活性成分中姜黄素、姜烯油的含量;红升麻活性成分中岩白菜素的用量;生半夏活性成分中β-谷甾醇的用量;地龙活性成分中谷氨酸的用量;乌骨鸡血中活性成分血红蛋白的用量,加上火酒,通过药理实验证明,6种药材提取物和火酒之间的相互作用具有协同作用,申请人在研究中发现,低剂量的药材提取物中,虽然大黄素、姜黄素、姜烯油、岩白菜素、β-谷甾醇、谷氨酸、血红蛋白的用量略低,但即具有明显的促进头皮新陈代谢、活化毛囊组织、有效地防止脱发、白发、刺激新发生长等作用,加入适量的火酒,促进其他活性成分的吸收、分布,加强了几种活性成分之间的协调性相互作用,更强于单独药物的加和效应,达到了协同增效、且增加安全性和稳定性的作用。
采用本发明的药物组合物所制备的酊剂用于治疗脱发及头发再生时,给药方案如下:
酊剂:涂于头部患处,每次1ml(约7喷),每日2次,从患处的中心开始涂抹,并用手按摩3~5分钟。每天的总量不得超过2ml。
实施例1
取大黄素60mg、姜黄素30mg、姜烯油40mg、岩白菜素150mg、β-谷甾醇30mg、谷氨酸9mg、血红蛋白100mg,加入50ml水和50℃火酒得组合物,再加入3倍重量份45%乙醇溶解,即得装量100ml酊剂。
实施例2
取大黄素50mg、姜黄素30mg、姜烯油40mg、岩白菜素120mg、β-谷甾醇30mg、谷氨酸9mg、血红蛋白100mg,加入60ml水和50℃火酒得组合物,再加入3倍重量份45%乙醇溶解,即得装量100ml酊剂。
实施例3
取大黄素60mg、姜黄素20mg、姜烯油40mg、岩白菜素150mg、β-谷甾醇30mg、谷氨酸9mg、血红蛋白90mg,加入60ml水和50℃火酒得组合物,再加入4倍重量份45%乙醇溶解,即得装量100ml酊剂。
实施例4
取大黄素40mg、姜黄素30mg、姜烯油30mg、岩白菜素150mg、β-谷甾醇30mg、谷氨酸9mg、血红蛋白90mg,加入50ml水和50℃火酒得组合物,再加入3倍重量份45%乙醇溶解,即得装量100ml酊剂。
实施例5
取大黄素50mg、姜黄素30mg、姜烯油40mg、岩白菜素150mg、β-谷甾醇30mg、谷氨酸8mg、血红蛋白90mg,加入50ml水和50℃火酒得组合物,再加入3倍重量份45%乙醇溶解,即得装量100ml酊剂。
实施例6
按照现有技术中国发明专利CN 201210237564.8说明书,由人参150g、侧柏叶150g、何首乌100g、甘草50g、老姜50g、骨碎补150g、旱莲草100g、冬虫夏草20g、女贞子50g、桑叶50g制备参归生发酊。
实验例一、原料处方筛选及用量筛选研究
对比样品1:去除首乌中筛选的活性成分成分大黄素,处方为:姜黄素、姜烯油、岩白菜素、β-谷甾醇、谷氨酸、血红蛋白、火酒,采用与实施例1的处方,制备得对比样品1,首先是相对于实施例1-5外观颜色不均一、稠度不均匀,通过采用培养小鼠触须毛囊游离器官和毛球细胞,研究对比样品1对体外培养的小鼠触须毛囊毛发生长的影响,通过7天一疗程的外用涂擦用药,经显微镜和MTT还原测定(单核细胞直接细胞毒性测定),结果显示:小鼠毛囊球部细胞有一点生长的迹象,但对比实施例1-5制备制得的酊剂效果差很多。
对比样品2:去除生姜中筛选的活性成分成分姜烯油,处方为:大黄素、姜黄素、岩白菜素、β-谷甾醇、谷氨酸、血红蛋白、火酒,采用与实施例1的处方,制备得对比样品2,同样采用对比样品1的实验方法和观察,结果显示:小鼠毛囊球部细胞有一点生长的迹象,但对比实施例1-5制备制得的酊剂效果差很多。
对比样品3:处方中加入首乌中活性成分大黄酚,同样采用对比样品1的实验方法和观察,结果显示:小鼠毛囊球部细胞有一点生长的迹象,但对比实施例1-5制备制得的酊剂效果差很多。
对比样品4:处方采用中药材原料组方:首乌15g、红升麻15g、生姜15g、生半夏15g、地龙8g、乌骨鸡血10g、火酒50%80ml,同样采用对比样品1的实验方法和观察,结果显示:小鼠毛囊球部细胞有生长的迹象,但对比实施例1-5筛选出每味中药材的活性成分制备制得的酊剂效果差很多,而且没有副作用。
对比样品5:处方去除血红蛋白,同样采用对比样品1的实验方法和观察,结果显示:小鼠毛囊球部细胞有一点生长的迹象,但对比实施例1-5制备制得的酊剂效果差很多。
对比样品6:加大大黄素用量为80mg,其他组分与实施例1等量,同样采用对比样品1的实验方法和观察,结果显示:小鼠毛囊球部细胞生长的迹象没有明显提升,反而,对比实施例1-5制备制得的酊剂效果稍差。
对比样品7:减少生半夏活性成分β-谷甾醇用量为10mg,其他组分与实施例1等量,同样采用对比样品1的实验方法和观察,结果显示:小鼠毛囊球部细胞生长的迹象不如对比实施例1-5制备制得的酊剂效果。
因此,通过对原来处方和用量的筛选出的本发明所制备得治疗脱发及头发再生的组合物及制剂才能达到理想的治疗效果。
表1:小鼠毛囊球部细胞生长试验
临床药效研究:
1.病例入选标准:20-60岁有脱发、掉发问题患者260例,其中有脂溢性脱发100例、斑秃100例、瘢痕性脱发60例。
2.治疗方法和疗程:涂于头部患处,每次1ml(约7喷),每日2次,从患处的中心开始涂抹,并用手按摩3~5分钟。每天的总量不得超过2ml每天早晚各1次,14天为一个疗程。
3.疗效判断标准:
(1)治愈:脱发症状明显改善,还会长出新的头发;
(2)好转:脱发症状明显改善;
(3)无效:脱发症状无改善,头发也没有再生。
有效率=(治愈+好转)/总例数x100%。
总结:通过上表对本发明的治疗脱发及头发再生的组合物及制剂进行处方、用量的筛选及现有技术产品的对比,在相同药物剂量下,本发明制剂对治疗脱发及头发再生的效果较现有公开的参归生发酊好,证明本发明制剂有明显的治疗脱发及头发再生的作用;另外,采用本发明所述首乌中大黄素活性成分高剂量组分制得的酊剂,其治疗效果并没有明显增强,反而,达不到理想的效果;减少所述生姜中姜黄素活性成分制得的酊剂疗效也达不到理想的治疗效果,因此,表明采用本发明所述的处方及处方用量范围,治疗脱发及头发再生效果良好。
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作出一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (10)
1.一种治疗脱发及头发再生的药物组合物,含有首乌活性成分0.04-0.08份、生姜活性成分0.03-0.10份、红升麻活性成分0.11-0.17份、生半夏活性成分0.01-0.04份、地龙活性成分0.007-0.11份、乌骨鸡血活性成分0.008-0.012份、火酒5-10份。
2.根据权利要求1所述的药物组合物,前述的首乌活性成分为大黄素;前述的生姜活性成分为姜黄素、姜烯油;前述的红升麻活性成分为岩白菜素;前述的生半夏活性成分为β-谷甾醇;前述的地龙活性成分为谷氨酸;前述的乌骨鸡血活性成分为血红蛋白。
3.根据权利要求1所述的药物组合物,按重量份计算,含有首乌活性成分0.06份、生姜活性成分0.07份、红升麻活性成分1.5份、生半夏活性成分0.03份、地龙活性成分0.009份、乌骨鸡血活性成分0.01份、火酒5-10份。
4.根据权利要求3所述的药物组合物,按重量份计算,含大黄素0.04-0.08份、姜黄素0.01-0.04份、姜烯油0.02-0.06份、岩白菜素0.11-0.17份、β-谷甾醇0.01-0.04份、谷氨酸0.007-0.11份、血红蛋白0.008-0.012份、火酒5-10份。
5.根据权利要求4所述的药物组合物,按重量份计算,含大黄素0.05-0.07份、姜黄素0.02-0.04份、姜烯油0.03-0.06份、岩白菜素0.12-0.16份、β-谷甾醇0.02-0.04、谷氨酸0.008-0.10份、血红蛋白0.009-0.011份、火酒5-10份。
6.根据权利要求4所述的药物组合物,按重量份计算,含大黄素0.06份、姜黄素0.03份、姜烯油0.04份、岩白菜素0.15份、β-谷甾醇0.03份、谷氨酸0.009份、血红蛋白0.01份、火酒5-10份。
7.一种治疗脱发及头发再生的药物制剂,由技术方案1-6任一项所述的药物组合物和辅料制成。
8.根据权利要求7所述的治疗脱发及头发再生的药物制剂,其剂型为酊剂。
9.根据权利要求1-6任一项所述的药物组合物或权利要求7或8所述的药物制剂在治疗脱发及头发再生中的应用。
10.一种治疗脱发及头发再生的酊剂的制备方法,取权利要求4或5或6所述的药物组合物,加入3-5倍的40-55%乙醇溶液,搅拌溶解,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010807949.8A CN111803613A (zh) | 2020-08-12 | 2020-08-12 | 一种治疗脱发及头发再生的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010807949.8A CN111803613A (zh) | 2020-08-12 | 2020-08-12 | 一种治疗脱发及头发再生的中药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111803613A true CN111803613A (zh) | 2020-10-23 |
Family
ID=72859312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010807949.8A Pending CN111803613A (zh) | 2020-08-12 | 2020-08-12 | 一种治疗脱发及头发再生的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111803613A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117357446A (zh) * | 2023-10-25 | 2024-01-09 | 广州市碧颜化妆品有限公司 | 一种防脱发组合物及其方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101128209A (zh) * | 2004-12-24 | 2008-02-20 | 都菲斯特股份有限公司 | 保健用制剂和治疗方法 |
CN106620574A (zh) * | 2015-10-28 | 2017-05-10 | 崔海霞 | 油风酊 |
CN109758567A (zh) * | 2019-03-26 | 2019-05-17 | 付家贵 | 一种治疗斑秃、脂溢性脱发的中药洗发喷液及其制备方法 |
-
2020
- 2020-08-12 CN CN202010807949.8A patent/CN111803613A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101128209A (zh) * | 2004-12-24 | 2008-02-20 | 都菲斯特股份有限公司 | 保健用制剂和治疗方法 |
CN106620574A (zh) * | 2015-10-28 | 2017-05-10 | 崔海霞 | 油风酊 |
CN109758567A (zh) * | 2019-03-26 | 2019-05-17 | 付家贵 | 一种治疗斑秃、脂溢性脱发的中药洗发喷液及其制备方法 |
Non-Patent Citations (1)
Title |
---|
代凯军等主编: "《美女天然保养DIY》", 28 February 2007, 上海科学普及出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117357446A (zh) * | 2023-10-25 | 2024-01-09 | 广州市碧颜化妆品有限公司 | 一种防脱发组合物及其方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101683503A (zh) | 具有养心强心作用的中药组合物 | |
CN102895410A (zh) | 女用阿胶固元膏 | |
CN113318214A (zh) | 一种乌发固发外用组合物及其制备方法 | |
CN101332246A (zh) | 治疗冠心病和心绞痛的中药制剂 | |
CN111803613A (zh) | 一种治疗脱发及头发再生的中药组合物 | |
CN102908391B (zh) | 一种治疗皮肤病的中药组合物及其制备方法和应用 | |
CN106334171B (zh) | 一种用于修复肝损伤的中药制剂及制备方法 | |
CN104274682A (zh) | 一种治疗煤工尘肺的中药组合物及其制备方法 | |
CN1399999A (zh) | 一种治疗恶性肿瘤病的药物及其制备方法 | |
CN108261506B (zh) | 一种治疗脱发的药物 | |
CN105213905A (zh) | 一种防治绝经后骨质疏松症的中药组合物及其应用 | |
CN105343761A (zh) | 一种治疗心肌梗死的中药组合物及其制备方法 | |
CN110760422A (zh) | 一种用于补肾的药酒 | |
CN108210596B (zh) | 一种降压中药及其制备降压膏敷贴的方法 | |
CN107233433A (zh) | 足癣散、制备方法及其应用和中药浸泡剂及其制备方法 | |
CN116115687B (zh) | 一种用于痛风的中药组合物及其制备方法和应用 | |
CN111437378B (zh) | 一种用于防治慢性心力衰竭的中药组合物、药物及其制备方法 | |
CN105935439B (zh) | 具有温肺降浊功效的中药及其制备方法和应用 | |
CN1088364C (zh) | 一种治疗缺血性脑病的中药组合物及其制备方法 | |
CN106039036A (zh) | 一种抗衰老的中药组合物 | |
WO2023282726A1 (ko) | 탈모방지 및 발모 효과를 갖는 한방조성물 | |
CN105727234A (zh) | 一种治疗脱发的中药组合物及其制备方法与应用 | |
CN105434890A (zh) | 一种治疗放射性口腔炎的中药组合物 | |
CN117482207A (zh) | 一种活血通络改善微循环的中药制剂及其制备方法 | |
CN116747267A (zh) | 一种生发中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201023 |
|
RJ01 | Rejection of invention patent application after publication |